Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198804 · ClinicalTrials.gov registry record · Phase 1
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
A Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT05198804 is a Phase 1 study that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT05198804, a Phase 1 study, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer.
Interventions
- DRUG Azenosertib
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2026-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05198804
The ClinicalTrials.gov registry entry for NCT05198804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azenosertib is the first listed.
NCT05198804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05198804 about?
NCT05198804 is a clinical study titled "A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer". This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer.
What is the current status of trial NCT05198804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2022-01-27. Estimated completion is 2026-01-19.
What interventions are being tested in trial NCT05198804?
The interventions under investigation include: Azenosertib (DRUG), Niraparib (DRUG).
Who is sponsoring clinical trial NCT05198804?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.